DUBLIN, April 25, 2022--(BUSINESS WIRE)--The "Adoptive Cell Therapy Market, by Type, By Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells.

Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.

Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period.

Key features of the study:

This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global adoptive cell therapy market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market

Story continues

Market Segmentation:

Global Adoptive Cell Therapy Market, By Type:

Global Adoptive Cell Therapy Market, By Application:

Global Adoptive Cell Therapy Market, By End User:

Hospitals

Cancer Treatment Centers

Global Adoptive Cell Therapy Market, By Region:

North America

U.S.

Canada

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

Europe

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

GCC

Israel

Rest of Middle East

Africa

South Africa

Central Africa

North Africa

Company Profiles

Novartis AG.

Gilead Sciences, Inc.

Castle Creek Biosciences, Inc

Lineage Cell Therapeutics, Inc.

Transgene SA

Cellectis

ImmunityBio, Inc

Sorrento Therapeutics

bluebird bio, Inc.

Arcellx

Sana Biotechnology, Inc.

Biodesix, Inc

Laurus Labs

For more information about this report visit https://www.researchandmarkets.com/r/kffwgd

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005562/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the original here:
Worldwide Adoptive Cell Therapy Industry to 2030 - Featuring Novartis, Gilead Sciences and Cellectis Among Others - ResearchAndMarkets.com - Yahoo...

The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.

The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation (HCT) or cellular therapy, such as CAR T-cell therapy or bispecific T-cell engagers (BiTEs), following initial failure of seroconversion after the first 2 vaccine doses, according to results from a study published in Cancer Cell.1

Among 75 patients who received allogeneic HCT (n = 30), autologous HCT (n = 26), CAR T-cell therapy (n = 10), or BiTEs (n = 9), and did not undergo seroconversion following the primary administration series of an mRNA-based SARS-CoV-2 vaccine, 59% of all evaluated patients developed antibodies following the third dose. Specifically, seroconversion rates were 63% for patients who received autologous HCT, 58% for those who received allogeneic HCT, 40% for patients administered CAR T-cell therapy, and 67% among patients given BiTEs.

Notably, the use of the approved vaccines BNT162b2, mRNA1273, or a mix-and-match strategy, all produced similar results.

A third dose should be considered for every transplant, CAR T-cell therapy, and BiTE recipient, as often as possible, co-study author Muhammad Bilal Abid, MD, MRCP, an assistant professor of medicine in the divisions of Hematology/Oncology and Infectious Diseases at the Medical College of Wisconsin, said in an interview with OncLive. For patients who do not respond to a third dose, a subset of patients will benefit from the reassessment of antibodies. If a third dose does not work, go for a fourth dose [and] this should be discussed with an infectious disease colleague at the center. There is a multidisciplinary collaborative approach that we have to provide.

Patients who have received HCT or cellular therapy have experienced poor outcomes after developing COVID-19.2 Notably, these patient populations have also shown lower response rates to SARS-CoV-2 vaccines, with responses for patients who underwent HCT and cellular therapy ranging from 50% to 80% and 20% to 30%, respectively.3,4

This study aimed to investigate the serological response to a third booster dose of a SARS-CoV-2 vaccine in patients who had received HCT or cellular therapy and did not seroconvert following the 2-dose primary vaccination series. Notably, patients who developed COVID-19 prior to the administration of the third dose were excluded from the study. Patients who had antibody testing within 2 weeks of the booster were also excluded.

To determine if patients seroconverted following a second vaccine dose, the AdviseDx SARS-CoV-2 IgG II assay was used to detect immunoglobulin G antibodies directed against the receptor-binding domain of the SARS-CoV-2 S1 subunit of the spike protein. The same assay was used to detect response following the booster dose. Patients were required to have at least 28 days between the second dose and booster shot, plus 14 days to antibody titer testing after receiving the booster.

The median age of patients who underwent seroconversion to the booster dose was 70 years (range, 31-77) compared with 66 years (range, 35-81) in patients who did not seroconvert following the booster (P = .04). Among male patients, 53% experienced seroconversion compared with 71% of female patients. In patients who went less than 12 months between HCT or cellular therapy and vaccination, 56% had seroconversion with the booster compared with 61% who had a duration of 12 months or longer between therapy and vaccination.

In patients who had seroconversion with the booster dose, the median interval between the second dose and booster was 172 days (range, 28-296) compared with 165 days (range, 93-223) for patients who failed to achieve seroconversion. The median interval between booster and humoral response assessment was 58 days (range, 14-140) in the patients who had seroconversion vs 47 days (range, 18-127) in the patients who did not.

The study authors pointed out that several factors may contribute to the continued lower response rates among patients who received CAR T-cell therapies compared with HCT or BiTEs. Preexisting, profound immunosuppression in this patient population could play a role, along with heavy pretreatment status, which could include prior HCT, lymphodepletion chemotherapy, and bridging chemotherapy. Toxicities such as cytokine release syndrome and immune effector cellassociated neurotoxicity syndrome requiring corticosteroids and tocilizumab (Actemra) may also contribute to lower vaccine responses.

Continued blunted responses are concerning among [patients who receive] CAR T-cell therapies, Abid said. They are certainly an incongruence with other reported literature. Recipients of CAR T-cell therapy are profoundly immunosuppressed by the time they get the CAR T-cell therapy primarily because of their underlying disease being so refractory.

Other studies will continue to explore the effectiveness of a third vaccine dose on these patient populations, along with research examining the effect of a fourth dose. Additionally, monoclonal antibodies could also have a role for aiding these patients.

We need to see the efficacy and safety data of monoclonal antibodies: sotrovimab [Xevudy] and Evusheld [tixagevimab and cilgavimab] in the preexposure setting for the prevention of progression of illness, Abid said. Thats something thats worth exploration.

Link:
COVID-19 Booster Yields Responses After Failure of Initial Vaccine Doses in Prior HCT or CAR T-Cell Therapy Recipients - OncLive

Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.

Frederick Locke, MD, vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy as well as program co-leader of Immuno-Oncology at Moffitt Cancer Center in Tampa, Florida, spoke to CancerNetwork about axicabtagene ciloleucel (Yescarta; axi-cel) for patients with relapsed/refractory large B-cell lymphoma (LBCL) and how patients can best benefit from this treatment.1 The recent approval of the therapy was for patients who received frontline chemoimmunotherapy and relapsed within 12 months based on results from the phase 3 ZUMA-7 trial (NCT03391466) which compared axi-cel with standard of care therapy.2

The main thing for community oncologists to realize is that CAR T-cell therapy can be given to patients who are older and have comorbidities. It can be given to younger patients, and if patients need the FDA-approved label, they should be referred in for evaluation and consideration of CAR T-cell therapy. Unfortunately, theres some misinformation out there in the community, in the Twitterverse, and elsewhere. These clinical trials that led to this approval enroll patients who had a poor prognosis, patients with high tumor burden. In fact CAR T-cell therapy works better than chemotherapy for patients with large amounts of tumor [burden], so the community oncologists should recognize that what we all want is whats best for the patients. The data are clear that CAR T-cell therapy, if given as a second-line treatment offers the best outcomes for patients with LBCL.

Originally posted here:
Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL - Cancer Network

In pursuit of its ongoing mission to achieve Victory Over Cancer, the V Foundation for Cancer Research announced its renewed support and a new $250,000 grant for the University of Floridas efforts to combat brain cancer in children. Combined with private support, a total of $600,000 in new funding will bolster critical research programs.

I am grateful for the V Foundations continued support, said Duane Mitchell, M.D., Ph.D., co-director of UFs Preston A. Wells Jr. Center for Brain Tumor Therapy and the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery at UFs College of Medicine, part of UF Health, the universitys academic health center. The V Foundation is one of the nations premier supporters of cancer research. Its an incredible honor to be a beneficiary of their generosity for a number of years. This sustained level of commitment from the V Foundation is vital in enabling my team to bring our research to the next level.

Brain cancer is now the leading cause of cancerrelated death in children, due in part to significantimprovements in outcomes for pediatric patients with more common cancers such as leukemia. Among other areas, Mitchell and his team have advanced novel immunotherapy treatments for medulloblastoma, the most commonmalignant brain tumor in children.

When asked about this partnership, Shane Jacobson, V Foundation chief executive officer, said that Mitchells research is truly game-changing.

While science has made significant strides against pediatric cancers, there are still so many questions about brain cancer, Jacobson said. We applaud his forward-thinking approach to stopping the disease. He is offering children with cancer and their families hope for a brighter future. We look forward to seeing the impact of his success.

Under Mitchells leadership, UF Health has pioneered an approach for pediatric brain tumorscalled adoptive T cell immunotherapy. Adoptive T cell therapy involves expanding tumor-reactive killer T cells to large numbers outside of a patient, reprogramming the cells to specifically target brain tumor cells, then reintroducing these immune cells into the body. This approach is currently undergoing evaluation in a firstinhuman clinical trial at UF Health.

This research is the culmination of years of hard work, said Mitchell, associate director of innovation and discovery at the UF Health Cancer Center and director of the UF Clinical and Translational Science Institute. Thank you to all of our donors for providing us the opportunity to continue this important research and to realize our vision to make a transformative impact on childrens lives.

Mitchells research team plans to advance this treatment platform by using genomictechnology to identify patientspecific antigens in medulloblastoma tumors, which are the most common malignant brain tumors in children. Once isolated and expanded outside of the body, these T cells will recognize unique tumor targets, called neoantigens. If the objectivesof the study are met, Mitchells team could significantly enhance the specificity and potency of this already promising platform and translate the findings into innovative clinical trials for children battlingbrain cancer.

Mitchell expects that immune therapies such as adoptive T cell therapy will lead to more effective treatments for those who do not benefit from chemotherapy, radiation, surgery or a combination of those treatments.

Since 2012, The V Foundation has generously supported UF Health, giving a total of more than $1.5 million, including $1.3 million to pediatric causes.

Media contact: Todd Taylor attmtaylor4@ufl.edu or 317-590-4399

Excerpt from:
Fighting pediatric cancer focus of V Foundation-UF Health collaboration - UF Health News

With further research, a selection of combination therapies could increase patient response in various cancer types.

Immunotherapy and radiotherapy have both improved survival rates for cancer, and combination therapies have potential to be even more effective and reduce recurrence. A recent review published in Frontiers in Oncology examined the mechanisms of immunotherapy and radiotherapy and how they can be combined and administered for maximum efficacy.

Radiotherapy is standard for cancerous tumors, with approximately 70% of patients with tumors being treated with it. It works by damaging the DNA of tumor cells within the irradiation field to control tumor growth. Data has increasingly shown that radiotherapy also leads to the release of myeloid-derived suppressor cells, M2-like tumor-associated macrophage, T-regulatory cells, N2 neutrophils, and immunosuppressive cytokines, promoting an immunosuppressive microenvironment.

Advances in technology have made radiotherapy more precise and effective, with proton heavy ion therapy being the most advanced option in the current treatment landscape. With the advancement of heavy ion therapy equipment and technology, the decline of treatment costs, and the advancement of research, heavy ion therapy will gradually be popularized in various countries across the world, study authors wrote.

Recent research has also found an abscopal effect caused by radiotherapy, further suggesting that radiotherapy affects not just the tumor site of treatment, but also the immune system.

Many preclinical studies have shown that irradiation triggers immunogenic cell death (ICD), which promotes the release of tumor-associated antigens, changes the tumor microenvironment (TME), and activates the immune system to exert an anti-tumor immune response, the authors wrote.

Radiation alone does not eradicate all malignant cells, though. Tumors with hypoxic cells can be resistant to radiotherapy compared with more oxygenated cells. Hypoxia can also lead to HIF signaling pathway activation, causing gene expression that can help tumors survive. A variety of other TME changes due to radiotherapy can also spur cell growth, and both short- and long-term adverse effects can occur.

Radiotherapy has seen advances in recent years, but as immunotherapy has gained traction, it has emerged as the most likely route to find a cancer cure, study authors wrote. The use ofimmune checkpoint inhibitors (ICIs) tumor vaccines, adoptive cell therapies, cytokine therapies, and other immunotherapies has increased in recent years.

Immunotherapy alone, however, is only used on a selection of tumor types in clinical practice and does not benefit all patients. Only approximately 10% to 30% of patients respond to single ICIs because of the complexity of cancer cell immune systems and tumor microenvironments (TMEs). Single ICIs or combination therapy is most likely to be effective in hot tumors, which have tumor-infiltrating lymphocytes (TILs), versus cold tumors, which do not have TILs. Immunotherapy can also lead to immune-related adverse events that can happen in all organs.

Given the resistance of hypoxic cells to radiotherapy and the generally low response to single immunotherapy, the 2 methods can be complementary. Radiotherapy can release tumor neoantigens, induce ICD, and have an anti-tumor effect in vivo.

Combinations of radiotherapy and immunotherapy have been increasingly studied, although large-scale clinical data are still limited. These combinations include ICIs and radiotherapy, tumor vaccine and radiotherapy, adoptive cell therapy and radiotherapy, and cytokine therapy plus radiotherapy.

Combining radiotherapy with ICIs targeting programmed cell death receptor 1 and programmed cell death ligand 1is one promising option that has been approved in certain advanced lung cancers and has been most effective in non-small cell lung cancer. However, many of these patients are still resistant to ICIs.

With tumor vaccines, which do not elicit tumor-eliminating immune response alone, radiotherapy may enhance immune response in vivo through several mechanisms. Various trials are underway investigating this combination.

Adoptive cell therapy, which is done by isolating immunoreactive cells from patients and reintroducing them to target antigen-specific tumor cells, is another increasingly studied treatment option that includes chimeric antigen receptor (CAR) T-cell therapy. Approximately 90% of patients experience relapse with CAR T-cell therapy, and early data show that radiotherapy may promote CAR T-cell effectiveness in solid tumors.

Cytokines, which regulate innate and adaptive immunity, have been shown to have significant anti-tumor activity but have dose-limiting severe toxicity that inhibits their efficacy. Studies are ongoing, but there may be potential for radiotherapy with adjuvant cytokine treatment or cytokine treatment followed by radiotherapy to increase effectiveness.

Study authors also highlight the development of multifunctional nanomaterials that can deliver immunomodulators and other drugs to tumors and improve the immunosuppressive environment. Multifunctional nanomaterials also have potential for use as radiosensitizers, potentially improving the effects of radiotherapy.

Overall, while some studies point to the effectiveness of combination radiotherapy and immunotherapy to improve treatment response, it is still unclear what sequence these therapies should be administered in and what the optimal timing is. The ideal radiotherapy fraction and dose selection are also questionable, as are the best immunotherapy-radiotherapy combinations for maximum anti-tumor response.

Toxicity and safety are also causes for further research, and it is still not clear which biomarkers are most useful to determine which patients may respond best to certain therapy combinations.

If the results of more and more clinical trials are positive, it will determine how best to integrate these models and optimize synergy, study authors wrote.

Reference

Yu S, Wang Y, He P, et al. Effective combinations of immunotherapy and radiotherapy for cancer treatment.Front Oncol. Published online February 7, 2022. doi:10.3389/fonc.2022.809304

More here:
Review Highlights Progress and Potential in Immunotherapy Plus Radiotherapy for Cancer Treatment - AJMC.com Managed Markets Network

Allogene Therapeutics, Inc.

ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021

ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogenes Multi-Pronged Strategy Targeting BCMA

BCMA Program Clinical Updates are Planned for Late 2022

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-605, the Companys next-generation AlloCAR T product candidate targeting BCMA for the treatment of multiple myeloma.

ALLO-605 is the Companys first TurboCAR product candidate. TurboCAR is a proprietary, next generation platform technology based on a programmable cytokine signaling, designed to control T cell exhaustion and to improve T cell function and potency. These properties may enable CAR T products to succeed in more difficult to treat hematologic malignancies and solid tumors. The FDA granted Fast Track designation to ALLO-605 in Q2 2021 based on the potential for the product candidate to address an unmet need for patients who have failed other standard multiple myeloma therapies. The Phase 1 study evaluating ALLO-605 is ongoing.

Orphan-drug designation marks an important step towards developing our anti-BCMA portfolio for patients with multiple myeloma and making allogeneic CAR T products readily available for patients, said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer. We look forward to providing an update on our BCMA clinical assets by the end of the year with an eye toward prioritizing a strategy for the next stage of development.

Orphan-drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the U.S. ODD granted therapies entitle companies to development incentives including tax credits for clinical testing and prescription drug user fee exemptions. If a product that has ODD subsequently receives the first FDA approval for the designated disease, the FDA may not approve any other applications to market the same biologic for the same indication for seven years, except in limited circumstances. ODD does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

Story continues

About ALLO-605ALLO-605, a next-generation AlloCAR T known as a TurboCAR, is an investigational product that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. This study uses ALLO-647, Allogene's proprietary monoclonal antibody (mAb), as a part of its differentiated lymphodepletion regimen. ALLO-605 incorporates Allogenes proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. Preclinical results with ALLO-605 were presented at the American Society of Hematology (ASH) annual meeting in December 2020. In June 2021, ALLO-605 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory multiple myeloma. The Phase 1 study evaluating ALLO-605 is underway.

About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell products with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit http://www.allogene.com and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to progress the IGNITE trial, including to provide an update at year-end on the IGNITE trial and other Allogene BCMA strategies; the potential for promising pre-clinical data to translate to positive clinical data; the ability to manufacture AlloCAR T products; and the potential benefits of TurboCAR technology and AlloCAR T products. Various factors may cause differences between Allogenes expectations and actual results as discussed in greater detail in Allogenes filings with the SEC, including without limitation in its Form 10-K for the year ended December 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T and TurboCAR are trademarks of Allogene Therapeutics, Inc.

Allogenes AlloCAR T programs utilize Cellectis technologies. The anti-BCMA AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs.

Allogene Media/Investor Contact:Christine CassianoChief Communications Officer(714) 552-0326Christine.Cassiano@allogene.com

View original post here:
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR T Cell Product Candidate, for the Treatment of Multiple...